Island Pharmaceuticals Limited (ASX:ILA)
Island Pharmaceuticals Limited (ASX:ILA) is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections.
The company's lead asset is ISLA-101, a drug with a well-established safety profile, that is being repurposed for the prevention and treatment of Dengue Fever and other mosquito (or vector) borne diseases.
390 million people are infected with Dengue Fever each year and it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death in the US, Europe and Australia
There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience.
Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.